Biography and Research Information
OverviewAI-generated summary
Maha Hanafi's research centers on the development of novel therapeutic agents, with a particular focus on pancreatic cancer. Her work involves the design and synthesis of compounds targeting specific molecular pathways implicated in cancer progression. Recent publications highlight efforts to discover agents that degrade key oncogenic proteins, such as PROTACs targeting ZFP91, and orally active compounds designed as sigma 2 receptor ligands. Further investigations explore the therapeutic vulnerabilities within the copper-KRAS-COX2 axis in pancreatic cancer. Hanafi also contributes to the review of emerging therapeutic strategies, such as rearranged during transfection (RET) kinase inhibitors. Her scholarship metrics include an h-index of 3 and 5 total publications with 87 citations.
Metrics
- h-index: 3
- Publications: 6
- Citations: 90
Selected Publications
-
Discovery of Novel 1h-Pyrazolo[3,4-D]Pyrimidine Derivatives as Brk/Ptk6 Inhibitors (2025)
-
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present) (2025)
-
Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441 (2024)
-
Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors (2024)
-
Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules (2023)
Collaboration Network
Top Collaborators
Nouri Neamati
University of Michigan–Ann Arbor (US)
3 shared publications
- Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91
- Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer
- Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer
Joyeeta Roy
University of Michigan–Ann Arbor (US)
2 shared publications
- Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer
- Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer
Armita Kyani
University of Michigan–Ann Arbor (US)
2 shared publications
- Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer
- Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer
Yibin Xu
University of Michigan–Ann Arbor (US)
2 shared publications
- Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer
- Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer
Duxin Sun
University of Michigan–Ann Arbor (US)
2 shared publications
- Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer
- Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer
Xinde Chen
University of Michigan–Ann Arbor (US)
1 shared publication
- Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91
John Takyi‐Williams
University of Michigan–Ann Arbor (US)
1 shared publication
- Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer
Essam Eldin A. Osman
Cairo University (EG)
1 shared publication
- Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer
Rima Mouawad
University of Michigan–Ann Arbor (US)
1 shared publication
- Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer
Bo Wen
University of Michigan–Ann Arbor (US)
1 shared publication
- Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer
Daniel W. Armstrong
University of Arkansas for Medical Sciences
1 shared publication
In database
- An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)
Brendan Frett
University of Arkansas for Medical Sciences
1 shared publication
In database
- An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)
Similar Researchers
Based on overlapping research topics
Zachary Heidrick
University of Arkansas at Fayetteville
Pancreatic and Hepatic Oncology Research
Cancer Treatment and Pharmacology
Drug Delivery Systems
Henry Ν. C. Wong
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Delivery Systems
Molecular Biology Techniques and Applications
Mathew Newman
Arkansas State University
Cancer Treatment and Pharmacology
Molecular Biology Techniques and Applications
Synthesis and biological activity
Zachary McConnell
University of Arkansas at Fayetteville
Pancreatic and Hepatic Oncology Research
Cancer Treatment and Pharmacology
Drug Delivery Systems
Odo Lovelyn Onyinyechi
University of Arkansas at Fayetteville
Cancer Treatment and Pharmacology
Drug Delivery Systems
Molecular Biology Techniques and Applications
Fengping Lv
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Molecular Biology Techniques and Applications
Protein Degradation and Inhibitors